Press releases

Press release
Medivir enters into licensing agreement with Ubiquigent for preclinical program USP7

Stockholm, Sweden— Medivir AB (Nasdaq Stockholm: MVIR) announced today that it had entered into a license agreement with Ubiquigent Limited (Ubiquigent)...

Read more
Press release
MEDIVIR ANNOUNCES FINAL OUTCOME OF THE OVERSUBSCRIBED RIGHTS ISSUE AND RESOLVES ON OVER-ALLOTMENT

The final result of Medivir AB’s (publ) (“Medivir” or the “Company”) rights issue of approximately SEK 170 million (the “Rights Issue”)...

Read more
Press release
Notice of extraordinary general meeting of Medivir AB (publ)

The shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the extraordinary...

Read more
Press release
MEDIVIR PROPOSES DIRECTED ISSUE OF APPROXIMATELY SEK 28 MILLION TO THE COMPANY’S EXISTING SPECIALIST INVESTOR LINC

In the rights issue, from which the preliminary results was announced on 5 February 2021 (the ”Rights Issue”), Bengt Julander (through...

Read more
Press release
PRELIMINARY OUTCOME IN MEDIVIR’S RIGHTS ISSUE – OVERSUBSCRIBED BY 93.5 PER CENT

On 11 December 2020 Medivir AB (publ) (”Medivir” or the “Company”) published its intention to carry out a rights issue of...

Read more
Press release
Medivir publishes prospectus relating to the rights issue – including new financial information

Medivir AB (“Medivir” or “the Company”) announces that the prospectus relating to Medivir’s rights issue (the “Rights Issue”) has been approved...

Read more
Press release
Resolutions at the extraordinary general meeting in Medivir on 13 January 2021

Resolution regarding reduction of the share capital without cancellation of shares  The extraordinary general meeting in Medivir Aktiebolag (publ) on 13...

Read more
Press release
Medivir presents MIV-818 data at ASCO Gastrointestinal Cancers Symposium

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a presentation entitled “Phase I study of the novel pro-drug...

Read more
Press release
Medivir enters into exclusive licensing agreement with IGM Biosciences for birinapant

Stockholm — Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which...

Read more